Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
arthritis
autoantibodies
cyclic citrullinated peptide
immune checkpoint inhibitors
immune-related adverse events
rheumatoid factor
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
08 05 2023
08 05 2023
Historique:
received:
03
07
2022
accepted:
31
10
2022
medline:
10
5
2023
pubmed:
4
1
2023
entrez:
3
1
2023
Statut:
ppublish
Résumé
Side effects of immune checkpoint inhibitors (ICIs), called immune-related adverse events (irAEs), closely resemble primary autoimmune or rheumatic diseases. We aimed to understand the clinical utility of rheumatic autoantibodies (rhAbs) for diagnosing irAEs. Patients without pre-existing autoimmune disease (pAID) who had cancer treated with ICI(s) treatment from 1/1/2011 to 12/21/2020 and a rhAb checked were retrospectively identified. Logistic regression assessed associations between autoantibodies and irAEs, cancer outcome, and survival. Specificity, sensitivity, and positive/negative predictive values (PPV, NPV) were estimated for key rhAbs and ICI-arthritis. Kaplan-Meier analyzed objective response rate (ORR) and overall survival (OS). A total of 2662 patients were treated with≥1 ICIs. One hundred and thirty-five without pAID had ≥ 1 rhAb tested. Of which 70/135(52%) were female; median age at cancer diagnosis was 62 years with most common cancers: melanoma (23%) or non-small cell lung cancer (21%), 96/135 (75%) were anti-PD1/PDL1 treated. Eighty had a rhAb ordered before ICI, 96 after ICI, and 12 before and after. Eighty-two (61%) experienced an irAE, 33 (24%) with rheumatic-irAE. Pre-ICI RF showed significant association with rheumatic-irAEs (OR = 25, 95% CI, 1.52-410.86, P = .024). Pre- and post-ICI RF yielded high specificity for ICI-arthritis (93% and 78%), as did pre- and post-ICI CCP (100% and 91%). Pre-ICI RF carried 93% NPV and pre-ICI CCP had 89% PPV for ICI-arthritis. No variables were significantly correlated with ORR. Any-type irAE, rheumatic-irAE and ICI-arthritis were all associated with better OS (P = .000, P = .028, P = .019). Pre-ICI RF was associated with higher odds of rheumatic-irAEs. IrAEs had better OS; therefore, clinical contextualization for rhAbs is critical to prevent unnecessary withholding of lifesaving ICI for fear of irAEs.
Sections du résumé
BACKGROUND
Side effects of immune checkpoint inhibitors (ICIs), called immune-related adverse events (irAEs), closely resemble primary autoimmune or rheumatic diseases. We aimed to understand the clinical utility of rheumatic autoantibodies (rhAbs) for diagnosing irAEs.
PATIENTS AND METHODS
Patients without pre-existing autoimmune disease (pAID) who had cancer treated with ICI(s) treatment from 1/1/2011 to 12/21/2020 and a rhAb checked were retrospectively identified. Logistic regression assessed associations between autoantibodies and irAEs, cancer outcome, and survival. Specificity, sensitivity, and positive/negative predictive values (PPV, NPV) were estimated for key rhAbs and ICI-arthritis. Kaplan-Meier analyzed objective response rate (ORR) and overall survival (OS).
RESULTS
A total of 2662 patients were treated with≥1 ICIs. One hundred and thirty-five without pAID had ≥ 1 rhAb tested. Of which 70/135(52%) were female; median age at cancer diagnosis was 62 years with most common cancers: melanoma (23%) or non-small cell lung cancer (21%), 96/135 (75%) were anti-PD1/PDL1 treated. Eighty had a rhAb ordered before ICI, 96 after ICI, and 12 before and after. Eighty-two (61%) experienced an irAE, 33 (24%) with rheumatic-irAE. Pre-ICI RF showed significant association with rheumatic-irAEs (OR = 25, 95% CI, 1.52-410.86, P = .024). Pre- and post-ICI RF yielded high specificity for ICI-arthritis (93% and 78%), as did pre- and post-ICI CCP (100% and 91%). Pre-ICI RF carried 93% NPV and pre-ICI CCP had 89% PPV for ICI-arthritis. No variables were significantly correlated with ORR. Any-type irAE, rheumatic-irAE and ICI-arthritis were all associated with better OS (P = .000, P = .028, P = .019).
CONCLUSIONS
Pre-ICI RF was associated with higher odds of rheumatic-irAEs. IrAEs had better OS; therefore, clinical contextualization for rhAbs is critical to prevent unnecessary withholding of lifesaving ICI for fear of irAEs.
Identifiants
pubmed: 36595378
pii: 6967750
doi: 10.1093/oncolo/oyac252
pmc: PMC10166164
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440-448Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Arthritis Res. 2002;4 Suppl 2:S1-5
pubmed: 12110150
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122
pubmed: 31464670
Ann Rheum Dis. 2017 Jan;76(1):43-50
pubmed: 27307501
Ann Rheum Dis. 2018 Mar;77(3):393-398
pubmed: 29146737
Nat Immunol. 2015 Jul;16(7):755-65
pubmed: 26006014
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251
pubmed: 31611368
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii68-vii74
pubmed: 31816082
Cancers (Basel). 2020 Feb 27;12(3):
pubmed: 32120803
Ann Med Intern Fenn. 1965;54(4):181-3
pubmed: 5853480
Ther Adv Musculoskelet Dis. 2021 Apr 12;13:1759720X211006963
pubmed: 33912248
J Rheumatol. 2020 Feb;47(2):166-175
pubmed: 31308203
Lupus. 2004;13(3):159-64
pubmed: 15119543
Dis Markers. 2013;35(6):727-34
pubmed: 24324289
Asia Pac J Clin Oncol. 2021 Jun;17(3):178-185
pubmed: 32717098
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35091456
Cancer. 2018 Sep 15;124(18):3706-3714
pubmed: 29975414
J Clin Rheumatol. 2022 Mar 1;28(2):e498-e505
pubmed: 34371516
Autoimmun Rev. 2018 Mar;17(3):284-289
pubmed: 29341936
Lancet. 1972 Nov 11;2(7785):1035-6
pubmed: 4116970
Curr Oncol Rep. 2018 Jul 31;20(9):72
pubmed: 30066230
Cancer Immunol Res. 2019 Jan;7(1):6-11
pubmed: 30425107
Front Immunol. 2019 Aug 14;10:1934
pubmed: 31474998
Ann Rheum Dis. 2017 Oct;76(10):1747-1750
pubmed: 28600350
JAMA Oncol. 2019 Mar 1;5(3):376-383
pubmed: 30589930
Front Oncol. 2021 Feb 11;10:585311
pubmed: 33643899
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
J Thorac Oncol. 2018 Nov;13(11):1771-1775
pubmed: 29935305
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34226279
Arthritis Care Res (Hoboken). 2017 Nov;69(11):1751-1763
pubmed: 27998041
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546243
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Ann Rheum Dis. 2021 Jan;80(1):36-48
pubmed: 32327425
Nat Rev Rheumatol. 2020 Dec;16(12):715-726
pubmed: 33154583
Lancet. 1972 Aug 26;2(7774):436
pubmed: 4115262
J Transl Med. 2018 Apr 2;16(1):82
pubmed: 29606147
Arthritis Rheumatol. 2021 Apr;73(4):553-565
pubmed: 33186490
Autoimmunity. 1990;5(3):232-3
pubmed: 2129756
Eur J Endocrinol. 2011 Feb;164(2):303-7
pubmed: 21088057
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Zentralbl Bakteriol B. 1978 Sep;167(3):253-61
pubmed: 104483